13.04.2023 22:30:00
|
U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab
INDIANAPOLIS, April 13, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the mirikizumab biologic license application (BLA) for the treatment of ulcerative colitis (UC). In the letter, the FDA cited issues related to the proposed manufacturing of mirikizumab, with no concerns about the clinical data package, safety, or label for the medicine.
"We remain confident in mirikizumab's pivotal Phase 3 clinical data and its potential to help people with ulcerative colitis," said Patrik Jonsson, Lilly executive vice president, president of Lilly Immunology and Lilly USA, and chief customer officer. "We are working diligently with the FDA and hope to launch mirikizumab in the U.S. as soon as possible."
Lilly recently received approval for mirikizumab as a first-in-class treatment for adults with moderately to severely active UC in Japan. In addition, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for mirikizumab as a first-in-class treatment for adults with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment. Regulatory decisions are anticipated in additional markets around the world in 2023.
About Lilly
Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram and LinkedIn. P-LLY
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about mirikizumab, FDA approval, and Lilly's products, and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with study findings to date, that future study results will be consistent with study results to date, that mirikizumab will receive certain regulatory approvals, or that it will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Refer to: | Carla Cox; cox_carla@lilly.com; +1-317-750-3923 (Lilly media) |
Joe Fletcher; jfletcher@lilly.com; +1-317-296-2884 (Lilly investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/us-food-and-drug-administration-issues-complete-response-letter-for-mirikizumab-301796847.html
SOURCE Eli Lilly and Company
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lillymehr Nachrichten
10.12.24 |
Eli Lilly stockt Dividende auf und plant massiven Aktienrückkauf - Aktie tiefer (dpa-AFX) | |
10.12.24 |
S&P 500-Wert Eli Lilly-Aktie: So viel Gewinn hätte ein Eli Lilly-Investment von vor einem Jahr eingefahren (finanzen.at) | |
06.12.24 |
MARKT USA/US-Arbeitsmarkt liefert Tendenz für die Wall Street (Dow Jones) | |
03.12.24 |
S&P 500-Titel Eli Lilly-Aktie: So viel hätte eine Investition in Eli Lilly von vor 10 Jahren abgeworfen (finanzen.at) | |
26.11.24 |
Handel in New York: S&P 500 letztendlich im Aufwind (finanzen.at) | |
26.11.24 |
Optimismus in New York: So entwickelt sich der S&P 500 am Nachmittag (finanzen.at) | |
26.11.24 |
Börse New York in Grün: S&P 500 im Plus (finanzen.at) | |
26.11.24 |
S&P 500-Papier Eli Lilly-Aktie: So viel Gewinn hätte ein Eli Lilly-Investment von vor 5 Jahren abgeworfen (finanzen.at) |
Analysen zu Eli Lillymehr Analysen
31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.24 | Eli Lilly Buy | Jefferies & Company Inc. |